MD Anderson Remains Top-Ranked Cancer Center
U.S. News & World Report named University of Texas MD Anderson Cancer Center in Houston as the No. 1 Adult Cancer Hospital in America for the fifth consecutive year. Memorial Sloan-Kettering Cancer Center in New York, Mayo Clinic in Rochester, Minnesota, Johns Hopkins Hospital in Baltimore and Dana-Farber/Brigham and Women’s Cancer Center in Boston, round out the top five, respectively. All five have highly regarded specialty centers for pleural mesothelioma, the rare and aggressive cancer caused by the inhalation of asbestos fibers. The expertise in mesothelioma treatment contributed to the top rankings in the 2019-...
Source: Asbestos and Mesothelioma News - August 28, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Study Explores New Treatment When Chemotherapy Fails
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma. Early indications of the four-center, phase II clinical trial are positive. The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth. The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma. The single-arm trial began i...
Source: Asbestos and Mesothelioma News - August 26, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

White House Asbestos Risk Forces Top Staff Relocation
The offices of some of President Donald Trump’s top aides, including his daughter Ivanka Trump and senior counselor Kellyanne Conway, have been temporarily relocated as the White House undergoes asbestos abatement work. An asbestos removal project is underway at 1600 Pennsylvania Avenue and is expected to be completed by the end of August. The abatement work will cost about $250,000, according to Pamela Pennington, press secretary for the U.S. General Services Administration. “The building has been, and remains, safe for occupancy as this work is being done as a precautionary measure,” Pennington said. In addition t...
Source: Asbestos and Mesothelioma News - August 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Clinical Trial Offering Personalized Immunotherapy for Mesothelioma
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still have a lot to lear...
Source: Asbestos and Mesothelioma News - August 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Australian Study Shows Treatment Advances for Peritoneal Mesothelioma
Patients with peritoneal mesothelioma undergoing a second cytoreductive surgery had a median survival of 92 months, according to a recent study at St. George Hospital and the University of South Wales in Sydney, Australia. That same group of patients also had a five-year survival rate of 71.8%, further illustrating the progress being made in treating the peritoneal subtype of this rare and aggressive cancer. The Journal of Surgical Oncology published the study in July 2019. The single-center study detailed the survival benefits of cytoreduction and perioperative intraperitoneal chemotherapy in colorectal, ovarian, appendic...
Source: Asbestos and Mesothelioma News - August 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Funding for first mesothelioma nurse specialist in West Midlands
Asbestos-related cancer patients in the West Midlands will soon have access to the region ’s first dedicated Mesothelioma clinical nurse specialist, while another post has been made full-time. (Source: Nursing Times)
Source: Nursing Times - August 8, 2019 Category: Nursing Source Type: news

Baylor Opens New Immunotherapy Clinical Trial for Mesothelioma
The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,” thoraci...
Source: Asbestos and Mesothelioma News - August 7, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Mesothelioma Treatment in Toronto Moves from SMART to SMARTER
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - July 31, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Once-Promising Drug Ofev Fails in Mesothelioma Clinical Trial
The search for a cure of mesothelioma hit another roadblock recently when a once-promising immunotherapy drug, combined with standard chemotherapy, failed to slow disease progression in a phase III study. The multicenter study covering 27 countries involved Ofev (nintedanib), a small-molecule enzyme inhibitor drug that had shown considerable potential in earlier studies. Lancet Respiratory Medicine published the trial results, signaling another setback for the highly anticipated use of certain immunotherapy drugs to treat mesothelioma. “Making significant improvements in systemic therapy for malignant pleural mesotheliom...
Source: Asbestos and Mesothelioma News - July 30, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Trump Signs 9/11 Victims Fund Extension
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - July 29, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cameron Sees No Need for National Mesothelioma Registry
Thoracic surgeon Dr. Robert Cameron, a longtime leader in the fight against pleural mesothelioma cancer, believes there is no benefit to establishing a government-funded national registry for the disease. While many of his colleagues support the idea of creating the first National Mesothelioma Registry, Cameron feels the time, effort and money spent would be better used elsewhere in helping patients. The National Institute of Occupational Safety and Health is currently conducting a National Mesothelioma Registry feasibility study for this rare and aggressive cancer. As part of that feasibility study, NIOSH opened a public ...
Source: Asbestos and Mesothelioma News - July 25, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Senate Passes 9/11 Victim Compensation Fund Extension
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

9/11 Victims Fund Passes Senate
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092. The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092. The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Death Rate Still Rising in Great Britain
Despite banning all forms and uses of asbestos 20 years ago, Great Britain still has one of the world’s highest rates of mesothelioma cancer, according to the government’s Health and Safety Executive report. The July 2019 report revealed the number of annual deaths from mesothelioma in the country still is peaking and expected to begin a gradual decline in 2020. The report included 2,523 deaths in 2017 (the last year available) from mesothelioma, the rare and aggressive cancer caused by exposure to asbestos. It estimates as many as 2,637 others could die in 2019. Great Britain, which comprises the nations of England, ...
Source: Asbestos and Mesothelioma News - July 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news